STOCK TITAN

[Form 4] Centessa Pharmaceuticals plc American Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Centessa Pharmaceuticals CEO Saurabh Saha executed significant stock transactions on June 20, 2025. The transactions involved:

  • Exercised 55,000 stock options at $3.85 per share
  • Subsequently sold 55,000 ordinary shares at weighted average price of $12.63 per share
  • Sales were executed under a pre-established Rule 10b5-1 trading plan from May 16, 2024

Post-transactions, Saha holds 221,017 ordinary shares directly and 38,000 shares indirectly through a trust. He retains 205,000 stock options exercisable until February 2033. The options vest monthly at 1/48th rate starting March 2023. This transaction resulted in an approximate gross profit of $483,000 before taxes and fees.

Il CEO di Centessa Pharmaceuticals, Saurabh Saha, ha effettuato importanti operazioni azionarie il 20 giugno 2025. Le operazioni comprendevano:

  • L'esercizio di 55.000 opzioni azionarie a 3,85 $ per azione
  • La successiva vendita di 55.000 azioni ordinarie a un prezzo medio ponderato di 12,63 $ per azione
  • Le vendite sono state eseguite nell'ambito di un piano di trading predefinito secondo la Regola 10b5-1, attivo dal 16 maggio 2024

Dopo le transazioni, Saha detiene direttamente 221.017 azioni ordinarie e indirettamente 38.000 azioni tramite un trust. Mantiene inoltre 205.000 opzioni azionarie esercitabili fino a febbraio 2033. Le opzioni maturano mensilmente a un ritmo di 1/48 a partire da marzo 2023. Questa operazione ha generato un profitto lordo approssimativo di 483.000 $ prima di tasse e commissioni.

El CEO de Centessa Pharmaceuticals, Saurabh Saha, realizó importantes transacciones de acciones el 20 de junio de 2025. Las transacciones incluyeron:

  • Ejercicio de 55,000 opciones sobre acciones a $3.85 por acción
  • Venta posterior de 55,000 acciones ordinarias a un precio promedio ponderado de $12.63 por acción
  • Las ventas se realizaron bajo un plan de negociación preestablecido según la Regla 10b5-1 desde el 16 de mayo de 2024

Tras las transacciones, Saha posee directamente 221,017 acciones ordinarias y 38,000 acciones indirectamente a través de un fideicomiso. Conserva 205,000 opciones sobre acciones ejercitables hasta febrero de 2033. Las opciones se consolidan mensualmente a una tasa de 1/48 desde marzo de 2023. Esta transacción generó una ganancia bruta aproximada de $483,000 antes de impuestos y comisiones.

Centessa Pharmaceuticals의 CEO Saurabh Saha2025년 6월 20일에 중요한 주식 거래를 수행했습니다. 거래 내용은 다음과 같습니다:

  • 주당 $3.8555,000 주식 옵션 행사
  • 이후 가중 평균 가격 주당 $12.6355,000 보통주 매도
  • 매도는 2024년 5월 16일부터 사전 설정된 Rule 10b5-1 거래 계획에 따라 실행됨

거래 후 Saha는 직접 221,017 보통주를 보유하고 있으며, 신탁을 통해 간접적으로 38,000 주를 보유하고 있습니다. 또한 2033년 2월까지 행사 가능한 205,000 주식 옵션을 보유하고 있습니다. 옵션은 2023년 3월부터 매월 1/48 비율로 베스팅됩니다. 이번 거래로 세금 및 수수료 차감 전 약 $483,000의 총이익이 발생했습니다.

Le PDG de Centessa Pharmaceuticals, Saurabh Saha, a réalisé d'importantes transactions d'actions le 20 juin 2025. Les opérations comprenaient :

  • Exercice de 55 000 options d'achat d'actions à 3,85 $ par action
  • Vente ultérieure de 55 000 actions ordinaires à un prix moyen pondéré de 12,63 $ par action
  • Les ventes ont été effectuées dans le cadre d'un plan de trading préétabli selon la règle 10b5-1 depuis le 16 mai 2024

Après ces transactions, Saha détient directement 221 017 actions ordinaires et indirectement 38 000 actions via un trust. Il conserve 205 000 options d'achat d'actions exerçables jusqu'en février 2033. Les options sont acquises mensuellement au rythme de 1/48 à partir de mars 2023. Cette opération a généré un bénéfice brut d'environ 483 000 $ avant impôts et frais.

Der CEO von Centessa Pharmaceuticals, Saurabh Saha, führte am 20. Juni 2025 bedeutende Aktiengeschäfte durch. Die Transaktionen umfassten:

  • Ausübung von 55.000 Aktienoptionen zu 3,85 $ pro Aktie
  • Anschließender Verkauf von 55.000 Stammaktien zum gewichteten Durchschnittspreis von 12,63 $ pro Aktie
  • Die Verkäufe wurden im Rahmen eines vorab festgelegten Rule 10b5-1 Handelsplans vom 16. Mai 2024 durchgeführt

Nach den Transaktionen hält Saha direkt 221.017 Stammaktien und indirekt 38.000 Aktien über einen Trust. Er besitzt weiterhin 205.000 ausübungsfähige Aktienoptionen bis Februar 2033. Die Optionen vesten monatlich mit einer Rate von 1/48 ab März 2023. Diese Transaktion führte zu einem ungefähren Bruttogewinn von 483.000 $ vor Steuern und Gebühren.

Positive
  • None.
Negative
  • None.

Il CEO di Centessa Pharmaceuticals, Saurabh Saha, ha effettuato importanti operazioni azionarie il 20 giugno 2025. Le operazioni comprendevano:

  • L'esercizio di 55.000 opzioni azionarie a 3,85 $ per azione
  • La successiva vendita di 55.000 azioni ordinarie a un prezzo medio ponderato di 12,63 $ per azione
  • Le vendite sono state eseguite nell'ambito di un piano di trading predefinito secondo la Regola 10b5-1, attivo dal 16 maggio 2024

Dopo le transazioni, Saha detiene direttamente 221.017 azioni ordinarie e indirettamente 38.000 azioni tramite un trust. Mantiene inoltre 205.000 opzioni azionarie esercitabili fino a febbraio 2033. Le opzioni maturano mensilmente a un ritmo di 1/48 a partire da marzo 2023. Questa operazione ha generato un profitto lordo approssimativo di 483.000 $ prima di tasse e commissioni.

El CEO de Centessa Pharmaceuticals, Saurabh Saha, realizó importantes transacciones de acciones el 20 de junio de 2025. Las transacciones incluyeron:

  • Ejercicio de 55,000 opciones sobre acciones a $3.85 por acción
  • Venta posterior de 55,000 acciones ordinarias a un precio promedio ponderado de $12.63 por acción
  • Las ventas se realizaron bajo un plan de negociación preestablecido según la Regla 10b5-1 desde el 16 de mayo de 2024

Tras las transacciones, Saha posee directamente 221,017 acciones ordinarias y 38,000 acciones indirectamente a través de un fideicomiso. Conserva 205,000 opciones sobre acciones ejercitables hasta febrero de 2033. Las opciones se consolidan mensualmente a una tasa de 1/48 desde marzo de 2023. Esta transacción generó una ganancia bruta aproximada de $483,000 antes de impuestos y comisiones.

Centessa Pharmaceuticals의 CEO Saurabh Saha2025년 6월 20일에 중요한 주식 거래를 수행했습니다. 거래 내용은 다음과 같습니다:

  • 주당 $3.8555,000 주식 옵션 행사
  • 이후 가중 평균 가격 주당 $12.6355,000 보통주 매도
  • 매도는 2024년 5월 16일부터 사전 설정된 Rule 10b5-1 거래 계획에 따라 실행됨

거래 후 Saha는 직접 221,017 보통주를 보유하고 있으며, 신탁을 통해 간접적으로 38,000 주를 보유하고 있습니다. 또한 2033년 2월까지 행사 가능한 205,000 주식 옵션을 보유하고 있습니다. 옵션은 2023년 3월부터 매월 1/48 비율로 베스팅됩니다. 이번 거래로 세금 및 수수료 차감 전 약 $483,000의 총이익이 발생했습니다.

Le PDG de Centessa Pharmaceuticals, Saurabh Saha, a réalisé d'importantes transactions d'actions le 20 juin 2025. Les opérations comprenaient :

  • Exercice de 55 000 options d'achat d'actions à 3,85 $ par action
  • Vente ultérieure de 55 000 actions ordinaires à un prix moyen pondéré de 12,63 $ par action
  • Les ventes ont été effectuées dans le cadre d'un plan de trading préétabli selon la règle 10b5-1 depuis le 16 mai 2024

Après ces transactions, Saha détient directement 221 017 actions ordinaires et indirectement 38 000 actions via un trust. Il conserve 205 000 options d'achat d'actions exerçables jusqu'en février 2033. Les options sont acquises mensuellement au rythme de 1/48 à partir de mars 2023. Cette opération a généré un bénéfice brut d'environ 483 000 $ avant impôts et frais.

Der CEO von Centessa Pharmaceuticals, Saurabh Saha, führte am 20. Juni 2025 bedeutende Aktiengeschäfte durch. Die Transaktionen umfassten:

  • Ausübung von 55.000 Aktienoptionen zu 3,85 $ pro Aktie
  • Anschließender Verkauf von 55.000 Stammaktien zum gewichteten Durchschnittspreis von 12,63 $ pro Aktie
  • Die Verkäufe wurden im Rahmen eines vorab festgelegten Rule 10b5-1 Handelsplans vom 16. Mai 2024 durchgeführt

Nach den Transaktionen hält Saha direkt 221.017 Stammaktien und indirekt 38.000 Aktien über einen Trust. Er besitzt weiterhin 205.000 ausübungsfähige Aktienoptionen bis Februar 2033. Die Optionen vesten monatlich mit einer Rate von 1/48 ab März 2023. Diese Transaktion führte zu einem ungefähren Bruttogewinn von 483.000 $ vor Steuern und Gebühren.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SAHA SAURABH

(Last) (First) (Middle)
C/O CENTESSA PHARMACEUTICALS PLC
3RD FL., 1 ASHLEY RD, ALTRINCHAM

(Street)
CHESHIRE X0 WA14 2DT

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Centessa Pharmaceuticals plc [ CNTA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares(1) 06/20/2025 M 55,000 A $3.85 276,017 D
Ordinary Shares(1) 06/20/2025 S(2) 55,000 D $12.6332(3) 221,017 D
Ordinary Shares(1) 38,000 I By trust(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option (right to buy) $3.85 06/20/2025 M 55,000 (5) 02/01/2033 Ordinary Shares(1) 55,000 $0 205,000 D
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $12.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4. These shares are held directly in a trust, for which the Reporting Person and his spouse serve as trustees.
5. 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023.
Remarks:
/s/ Gregory Weinhoff, attorney-in-fact 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CNTA shares did CEO Saurabh Saha sell on June 20, 2025?

CEO Saurabh Saha sold 55,000 ordinary shares of CNTA on June 20, 2025 at a weighted average price of $12.6332 per share. The shares were sold in multiple transactions at prices ranging from $12.50 to $12.80.

What was the total value of CNTA shares sold by CEO Saurabh Saha?

Based on the weighted average sale price of $12.6332 per share for 55,000 shares, the total value of the transaction was approximately $694,826.

How many CNTA shares does CEO Saurabh Saha still own after the June 2025 transaction?

After the transaction, CEO Saurabh Saha owns 221,017 shares directly and 38,000 shares indirectly through a trust, for a total of 259,017 shares. He also holds 205,000 stock options.

Was CNTA CEO Saha's stock sale part of a pre-planned trading arrangement?

Yes, the sales were executed pursuant to a Rule 10b5-1 trading plan that was adopted by Saurabh Saha on May 16, 2024, approximately 13 months before the transaction.

What is the exercise price of CNTA CEO Saha's stock options?

The stock options have an exercise price of $3.85 per share and expire on February 1, 2033. The options vest in equal monthly installments, with 1/48th of the shares vesting monthly starting March 1, 2023.
Centessa Pharmaceuticals Plc

NASDAQ:CNTA

CNTA Rankings

CNTA Latest News

CNTA Latest SEC Filings

CNTA Stock Data

1.74B
118.69M
1.29%
97.12%
4.14%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
ALTRINCHAM, CHESHIRE